Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016

被引:8
|
作者
Taylor, Melissa A. [1 ]
Switchenko, Jeffery [2 ]
Stokes, William [3 ]
Patel, Mihir R. [3 ]
McDonald, Mark [3 ]
Steuer, Conor [3 ]
Aiken, Ashley [3 ]
Beitler, Jonathan J. [3 ]
Shin, Dong M. [3 ]
Saba, Nabil F. [3 ]
机构
[1] Emory Univ, Sch Med, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA
[3] Emory Univ, Winship Canc Inst, 1365 Clifton Rd, Atlanta, GA 30322 USA
来源
CANCER MEDICINE | 2021年 / 10卷 / 17期
关键词
elderly population; HPV; incidence trends; squamous cell carcinoma of the head and neck; HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; OLDER PATIENTS; UNITED-STATES; PREVALENCE; ADULTS; MALES;
D O I
10.1002/cam4.4134
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Tobacco and alcohol use are risk factors for Squamous Cell Carcinoma of the Head and Neck (SCCHN); however, there is growing recognition of HPV as a risk factor for SCCHN. HPV-related SCCHN is thought to affect mostly middle-aged individuals but as the US population ages, it is important to evaluate the change in incidence of HPV- and non-HPV-related SCCHN in individuals who are >= 65 years old. Methods This was a retrospective study using data from a population-based cancer registry (SEER) to identify individuals >= 65 years old diagnosed with SCCHN between 2000 and 2016 also stratified by sex, race, and birth cohort. The subgroups of HPV-associated and non-HPV associated sites were analyzed independently. The incidence per year was calculated and joinpoint detection was used to identity significant changes in incidence trends and annual percent change (APC). Results For HPV-associated sites from 2000 to 2016, there was an average annual rate of 10.8 per 100,000 individuals with an APC of 2.92% (p = <0.05). For HPV- and non-HPV-related SCCHN males had a higher annual rate compared to females, 54.5 versus 18.0 in non-HPV-related and 19.1 versus 4.4 in HPV-related sites. For non-HPV-related sites there was a decrease in APC across all stratified groups. For HPV-related sites there was an increase in APC across all stratified groups, especially males (APC 8.82% 2006-2016 p < 0.05) and White individuals (APC 8.19% 2006-2016 p < 0.05). When stratified by birth cohort, HPV-related SCCHN sites had a higher APC in ages 65-69 (8.38% p < 0.05) and 70-74 (8.54% p < 0.05). Conclusion Among the population >= 65 years old from 2000 to 2016, the incidence rate for HPV-related SCCHN sites has increased across all stratified groups, especially in White individuals, males, and age groups 65-74. The incidence rate for non-HPV-related sites has decreased across all stratified groups during this time.
引用
收藏
页码:6070 / 6077
页数:8
相关论文
共 50 条
  • [31] VALIDATION OF A CLAIMS-BASED ALGORITHM FOR IDENTIFICATION OF PATIENTS WITH RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE US
    Korytowsky, B.
    Radtchenko, J.
    Abraham, P.
    Klinefelter, P.
    Shaw, J. W.
    Feinberg, B.
    VALUE IN HEALTH, 2018, 21 : S218 - S218
  • [32] Carboplatin/paclitaxel-based radiochemotherapy is not inferior to cisplatin-based regimens in squamous cell carcinoma of head and neck (SCCHN)
    Maring, S.
    Elsayad, K.
    Ernst, I
    Haverkamp, U.
    Eich, H. T.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S89 - S89
  • [33] Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Mehra, Ranee
    Egloff, Ann Marie
    Li, Shuli
    Yang, Donghua
    Wang, Lin
    Zhu, Fang
    Forastiere, Arlene A.
    Burtness, Barbara
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis
    Kies, M. S.
    Gibson, M. K.
    Kim, S. W.
    Savvides, P.
    Blumenschein, G. R., Jr.
    Worden, F.
    Chen, H.
    Grandis, J. R.
    Argiris, A. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Analysis of advanced cutaneous squamous cell carcinoma of the head and neck in a largely rural population
    Mechels, Halie N.
    Bormann, Jordan L.
    Frohm, Marcus L.
    Spanos, William C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB197 - AB197
  • [36] Incidence and mortality of renal cell carcinoma in the US: A SEER-based study investigating trends over the last four decades.
    Gad, Mohamed M.
    Saad, Anas M.
    Al-Huseini, Muneer J.
    Ruhban, Inas A.
    Sonbol, Mohamad B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN).
    Li, Qinyang
    Guan, Jian
    Zhang, Yue
    Chen, Min
    Li, Lu
    Xiao, Nanjie
    Yang, Mi
    Dai, Yongmei
    Zhang, Chi
    Chen, Longhua
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] PREDICTORS OF IMRT AND CONFORMAL RADIOTHERAPY USE IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: A SEER-MEDICARE ANALYSIS
    Sher, David J.
    Neville, Bridget A.
    Chen, Aileen B.
    Schrag, Deborah
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E197 - E206
  • [39] A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)
    Guan, Jian
    Li, Qinyang
    Zhang, Yue
    Xiao, Nanjie
    Chen, Min
    Zhang, Yaowei
    Li, Lu
    Chen, Longhua
    ONCOTARGET, 2016, 7 (06) : 7110 - 7119
  • [40] Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry
    Cummings, Michael A.
    Ma, Sung Jun
    Van der Sloot, Paul
    Milano, Michael T.
    Singh, Deepinder P.
    Singh, Anurag K.
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (04)